It was also well established that IgE-mediated immune pathways were central to asthma, which made serum IgE an intuitive choice to be the first biomarker featured in a biologic clinical trial for asthma (the anti-IgE therapy, omalizumab) [9]. Here, IGHE is linked to asthma.